I agree completely with you Rock! If you look at what is going on across the World, the infection rates are going up but the Mortality rate is actually going down. Is this due to better care (maybe) or is it likely due to the virus attenuating (more likely). Therefore, the most significantly significant difference between Leronlimab and the SoC will have been seen already. The longer this trials goes, the more people will survive SoC. That’s great news for the world, not so great for Leronlimab. So losing a point in the p value now means nothing compared to getting the drug data out now and pushing for approval. Not only will Leronlimab save lives now, but will hopefully prove effective in Long Haulers. I think NP and the BoD are making a grave mistake in not unblinding the Data now. If we have a 20-25% improvement in mortality (and that is a low ball estimate in my opinion) no one is going to care that the p value was increased just because we unblinded the data to get to the truth.
UNBLIND NOW!!! IMO
News 
Market Data 
Discover 
